148 related articles for article (PubMed ID: 35167392)
1. Investigating the efficacy of osimertinib and crizotinib in phase 3 clinical trials on anti-cancer treatment-induced cardiotoxicity: are real-world studies the way forward?
Kobat H; Elkonaissi I; Foreman E; O'Brien M; Dorak MT; Nabhani-Gebara S
J Oncol Pharm Pract; 2023 Apr; 29(3):646-662. PubMed ID: 35167392
[TBL] [Abstract][Full Text] [Related]
2. Real-world data on treatment outcomes in
Dal Maso A; Lorenzi M; Ferro A; Pilotto S; Cecere F; Follador A; Polo V; Del Conte A; Sartori G; Giavarra M; Scattolin D; Indraccolo S; Frega S; De Maglio G; Menis J; Bonanno L; Calabrese F; Guarneri V; Conte P; Pasello G
Future Oncol; 2021 Jul; 17(19):2513-2527. PubMed ID: 33988036
[TBL] [Abstract][Full Text] [Related]
3. Osimertinib, a third-generation EGFR tyrosine kinase inhibitor: A retrospective multicenter study of its real-world efficacy and safety in advanced/recurrent non-small cell lung carcinoma.
Kishikawa T; Kasai T; Okada M; Nakachi I; Soda S; Arai R; Takigami A; Sata M
Thorac Cancer; 2020 Apr; 11(4):935-942. PubMed ID: 32129931
[TBL] [Abstract][Full Text] [Related]
4. Comparison of cardiovascular effects of crizotinib and chemotherapy in ALK-positive advanced non-small-cell lung cancer.
Wilner KD; Usari T; Polli A; Kim EE
Future Oncol; 2019 Apr; 15(10):1097-1103. PubMed ID: 30652510
[TBL] [Abstract][Full Text] [Related]
5. Osimertinib in advanced EGFR-T790M mutation-positive non-small cell lung cancer patients treated within the Special Use Medication Program in Spain: OSIREX-Spanish Lung Cancer Group.
Provencio M; Terrasa J; Garrido P; Campelo RG; Aparisi F; Diz P; Aguiar D; García-Giron C; Hidalgo J; Aguado C; González JG; Esteban E; Gómez-Aldavarí L; Moran T; Juan O; Chara LE; Marti JL; Castro RL; Ortega AL; Moreno EM; Coves J; Sánchez Peña AM; Bosch-Barrera J; Gastaldo AS; Núñez NF; Del Barco E; Cobo M; Isla D; Majem M; Navarro F; Calvo V
BMC Cancer; 2021 Mar; 21(1):230. PubMed ID: 33676426
[TBL] [Abstract][Full Text] [Related]
6. A real-world study of second or later-line osimertinib in patients with EGFR T790M-positive NSCLC: the final ASTRIS data.
Cheema P; Cho BC; Freitas H; Provencio M; Chen YM; Kim SW; Wu YL; Passaro A; Martin C; Tiseo M; Chang GC; Park K; Solomon B; Burghuber O; Laskin J; Wang Z; Lee SY; Hu Y; Vansteenkiste J; Zhang HL; Hanrahan E; Geldart T; Taylor R; Servidio L; Li J; Marinis F
Future Oncol; 2023 Jan; 19(1):61-75. PubMed ID: 36656302
[TBL] [Abstract][Full Text] [Related]
7. Crizotinib-induced simultaneous multiple cardiac toxicities.
Oyakawa T; Muraoka N; Iida K; Kusuhara M; Kawamura T; Naito T; Takahashi T
Invest New Drugs; 2018 Oct; 36(5):949-951. PubMed ID: 29717400
[TBL] [Abstract][Full Text] [Related]
8. Dramatic response to osimertinib combined with crizotinib in EGFR T790 M mutation only in blood and Met amplification only in tumor tissue expressive non-small cell lung cancer: A case report.
Li D; Gui Q; Xu C; Shen M; Chen K
Medicine (Baltimore); 2021 Jul; 100(30):e26375. PubMed ID: 34397683
[TBL] [Abstract][Full Text] [Related]
9. Osimertinib induced cardiac failure and QT-prolongation in a patient with advanced pulmonary adenocarcinoma.
Bardaro F; Stirpe E
J Oncol Pharm Pract; 2022 Jun; 28(4):989-994. PubMed ID: 35037771
[TBL] [Abstract][Full Text] [Related]
10. Osimertinib for Japanese patients with T790M-positive advanced non-small-cell lung cancer: A pooled subgroup analysis.
Hirashima T; Satouchi M; Hida T; Nishio M; Kato T; Sakai H; Imamura F; Kiura K; Okamoto I; Kasahara K; Uchida H; Vowler SL; Mitsudomi T
Cancer Sci; 2019 Sep; 110(9):2884-2893. PubMed ID: 31265163
[TBL] [Abstract][Full Text] [Related]
11. Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study.
Cheng Y; He Y; Li W; Zhang HL; Zhou Q; Wang B; Liu C; Walding A; Saggese M; Huang X; Fan M; Wang J; Ramalingam SS
Target Oncol; 2021 Mar; 16(2):165-176. PubMed ID: 33544337
[TBL] [Abstract][Full Text] [Related]
12. Data from real world to evaluate the efficacy of osimertinib in non-small cell lung cancer patients with central nervous system metastasis.
Xing P; Mu Y; Hao X; Wang Y; Li J
Clin Transl Oncol; 2019 Oct; 21(10):1424-1431. PubMed ID: 30864019
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of osimertinib for preventing leptomeningeal metastasis derived from advanced EGFR-mutated non-small cell lung cancer: a propensity-matched retrospective study.
Wang X; Cai J; Zeng Z; Liu A
BMC Cancer; 2021 Jul; 21(1):873. PubMed ID: 34330231
[TBL] [Abstract][Full Text] [Related]
14. Overall Survival with Osimertinib in Untreated,
Ramalingam SS; Vansteenkiste J; Planchard D; Cho BC; Gray JE; Ohe Y; Zhou C; Reungwetwattana T; Cheng Y; Chewaskulyong B; Shah R; Cobo M; Lee KH; Cheema P; Tiseo M; John T; Lin MC; Imamura F; Kurata T; Todd A; Hodge R; Saggese M; Rukazenkov Y; Soria JC;
N Engl J Med; 2020 Jan; 382(1):41-50. PubMed ID: 31751012
[TBL] [Abstract][Full Text] [Related]
15. ASTRIS: a global real-world study of osimertinib in >3000 patients with
Marinis F; Wu YL; de Castro G; Chang GC; Chen YM; Cho BC; Freitas HC; Jiang L; Kim SW; Martin C; Metro G; Provencio M; Vansteenkiste J; Vicente D; Zhou Q; Miranda MF; Bakker NA; Rigas JR; Cheema PK
Future Oncol; 2019 Sep; 15(26):3003-3014. PubMed ID: 31339357
[No Abstract] [Full Text] [Related]
16. Osimertinib in Japanese patients with EGFR T790M mutation-positive advanced non-small-cell lung cancer: AURA3 trial.
Akamatsu H; Katakami N; Okamoto I; Kato T; Kim YH; Imamura F; Shinkai M; Hodge RA; Uchida H; Hida T
Cancer Sci; 2018 Jun; 109(6):1930-1938. PubMed ID: 29697876
[TBL] [Abstract][Full Text] [Related]
17. Representativeness of Phase III Trial for Osimertinib in Pretreated Advanced EGFR-Mutated Non-small-cell Lung Cancer Patients and Treatment Outcomes in Clinical Practice.
Lin L; Smit EF; de Langen AJ; van Balen DEM; Beijnen JH; Huitema ADR
Target Oncol; 2022 Jan; 17(1):53-59. PubMed ID: 34894319
[TBL] [Abstract][Full Text] [Related]
18. Treatment Sequencing in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer in Japan: A Real-World Observational Study.
Goto Y; Yamamoto N; Masters ET; Kikkawa H; Mardekian J; Wiltshire R; Togo K; Ohe Y
Adv Ther; 2020 Jul; 37(7):3311-3323. PubMed ID: 32472430
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of first-line osimertinib treatment and postprogression patterns of care in patients with epidermal growth factor receptor activating mutation-positive advanced non-small cell lung cancer (Reiwa study): study protocol of a multicentre, real-world observational study.
Watanabe K; Yoh K; Hosomi Y; Usui K; Naka G; Kishi K; Uemura K; Ohashi Y; Kunitoh H
BMJ Open; 2022 Jan; 12(1):e046451. PubMed ID: 34983748
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With EGFR T790M-Mutated Non-Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor: West Japan Oncology Group 8715L Phase 2 Randomized Clinical Trial.
Akamatsu H; Toi Y; Hayashi H; Fujimoto D; Tachihara M; Furuya N; Otani S; Shimizu J; Katakami N; Azuma K; Miura N; Nishino K; Hara S; Teraoka S; Morita S; Nakagawa K; Yamamoto N
JAMA Oncol; 2021 Mar; 7(3):386-394. PubMed ID: 33410885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
